At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
Tralokinumab Dose 1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Placebo, Tralokinumab Dose 1, and 2 other interventions for Atopic Dermatitis. Completed, enrolled 204 participants across 57 sites in 6 countries.
Detailed Summary
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, Germany, Japan, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionNov 2015
Study CompletionFeb 2016
TodayJul 2026
First PostedJan 27, 2015
Enrollment StartJan 23, 2015
Primary CompletionNov 27, 2015
Study CompletionFeb 5, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.4 years ago
Interventions
Placeboother
Subcutaneous injection with placebo
Tralokinumab Dose 1biological
Subcutaneous injection with tralokinumab
Tralokinumab Dose 2biological
Subcutaneous injection with tralokinumab
Tralokinumab Dose 3biological
Subcutaneous injection with tralokinumab